Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
290 Leser
Artikel bewerten:
(1)

Investis Digital Announces Strategic Partnership with Clinpal

Alliance creates the world's first end-to-end, fully connected platform for subject recruitment.

LONDON and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Investis Digital, a leading global digital communications company announced that they have entered into a strategic partnership with eClinicalHealth (Clinpal). This alliance combines Investis Digital's propriety framework, Connected Content, known for attracting, targeting and engaging hard-to-reach patient populations, and Clinpal's cloud-based platform, which connects those patients, study teams and sites during a clinical trial.

This partnership addresses two critical unmet needs - operational inefficiency and lack of transparency in the recruitment process for teams conducting clinical studies. This integrated approach has proven to provide faster, patient-centric, and cost-effective recruitment.

Ian Koenig, SVP, Global Head of Life Sciences at Investis Digital comments, "We've taken apart everything that has to do with the patient recruitment flow model and rebuilt it more efficiently. Our clients no longer have to wonder why their enrollment curve looks the way it does. Through our platform and coordinated effort, they can dive deep into the data at a country, region, and site level in real-time, and make data-driven actions on their recruitment efforts."

Key benefits of the integrated solution include:

  • Advanced subject profiling
  • Omni-channel engagement tactics
  • Sophisticated pre-screening
  • Candidate flow-through management
  • Real-time analytics
  • Clinical operations support

The Investis Digital-Clinpal solution provides comprehensive stakeholder mapping, digital and non-digital content creation, analytics, and reporting, alongside a vast array of tools, including e-consent and EDC, to fulfill any patient recruitment need study teams may have. Its continuous feedback loop allows study teams to react quickly to ensure optimal operational efficiency. This solution also asserts HIPPA and GDPR compliance.

"Patient engagement and managing the warm handover to study sites is at the heart of clinical trials. With Investis Digital's powerful performance marketing solutions coupled with our scalable platform that allows you to run highly complex studies from rare and orphan diseases to global mega-trials will potentially revolutionize the future of patient recruitment," said Karl Landert, CEO of eClinicalHealth.

About Investis Digital

Investis Digital has been at the forefront of digital communications for two decades. Over time we've gained deep sector knowledge, invested in leading technologies, and built lasting and trusted relationships with more than 1600 global companies, including Ascential, Anglo American, Rolls-Royce, Fruit of the Loom and Vodafone.

Through a proprietary approach we call Connected Content, we unite compelling communications, intelligent digital experiences and performance marketing to help companies build deeper connections with audiences and drive business performance.

We tell?brand stories through strategic and engaging content that meets your audiences at the right time, in the right place, with the right message.
We build and run?intelligent websites and digital experiences that are rapidly deployed and strategically measured, underpinned by our secure, world-leading Connect.ID technology and 24/7 service.
We find?the audiences that matter most?through powerful?performance marketing solutions that optimize and amplify your brand across all touchpoints.

This unique blend of expertise, technology and "always on" service allow clients to trust that their digital footprint and brand reputation is secure and protected 24/7 by our dedicated team of 500 digital experts across 9 global offices. To learn more on how Investis Digital has been powering digital communications since 2000, please visit:?www.InvestisDigital.com?

About eClinicalHealth Limited

Headquartered in Scotland, eClinicalHealth Limited, developers of the Clinpal remote research platform, was founded in 2012 to provide innovative clinical trial solutions. The company is committed to developing patient-centric innovation in clinical trial processes and technology with pharmaceutical companies, CROs and other service and technology providers. eClinicalHealth has been one of the leaders in providing technology for remote decentralized ('virtual') trials.

Contact information:
MaryAlina Vettichira-Mathew
MaryAlina@investisdigital.com

Logo - https://mma.prnewswire.com/media/784164/Investis_Digital_Logo.jpg

© 2021 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.